Methoxetamine: Difference between revisions

Nav

(View all pending changes)

[unchecked revision]

[pending revision]

VisualWikitext

Latest revision as of 17:24, 26 May 2026

Research material, Dissociative

Methoxetamine

Experience

👥 No personal reports yet

⚕ No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

Multi-route dose ladders (Erowid, very tentative)0

Erowid's dosage documentation for methoxetamine (MXE)^[1] is marked "very tentative" throughout and

notes that "doses reported by different users vary by a large amount."

Insufflated:

Threshold: 5-20 mg; Light: 10-50 mg; Common: 20-60 mg; Strong: 25-100+ mg

Oral:

Threshold: 8-20 mg; Light: 10-30 mg; Common: 40-60 mg; Strong: 50-100+ mg

Sublingual/buccal:

Threshold: 5-10 mg; Light: 8-25 mg; Common: 15-50 mg; Strong: 40-100+ mg

Intramuscular:

Threshold: 3-8 mg; Light: 5-20 mg; Common: 15-30 mg; Strong: 20-80+ mg

Timing data are not provided by Erowid. The wide variability between users (some report strong effects at 50 mg; others minimal at the same dose) and Erowid's tentative qualifier should be reflected in

any presentation.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

No interactions reported yet.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary

Classes

Research material, Dissociative

Pharmacy

Pharmacology

Purported mechanism

NMDA antagonist; SERT inhibitor; sigma-1 agonist

↑ Erowid. Methoxetamine Dosage. Erowid.org. https://www.erowid.org/chemicals/methoxetamine/methoxetamine_dose.shtml. Accessed 2026-05-26.

[erowid-mxe-dose-1] Erowid. Methoxetamine Dosage. Erowid.org. https://www.erowid.org/chemicals/methoxetamine/methoxetamine_dose.shtml. Accessed 2026-05-26.

[1]

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Methoxetamine
+| generic            = Methoxetamine
-| classes           = Research material, Dissociative
+| brand              =
-| mechanism         = NMDA antagonist; SERT inhibitor; sigma-1 agonist
+| structure          =
+| classes            = Research material, Dissociative
+| mechanism          = NMDA antagonist; SERT inhibitor; sigma-1 agonist
+| uses               =
+| starting_dose      =
+| preparations       =
+| fda_max           =
+| routes             =
+| onset              =
+| duration           =
+| halflife           =
+| bioavailability    =
+| pregnancy          =
+| legal              =
+| intro              =
+| pharmacokinetics   =
+| pharmacodynamics   =
+| indications        =
+| dosing             =
+<titration slug="erowid-dose-multi-route" author="erowid-claude"
+title="Multi-route dose ladders (Erowid, very tentative)">
+Erowid's dosage documentation for methoxetamine (MXE)<ref
+name="erowid-mxe-dose">Erowid. Methoxetamine Dosage. Erowid.org.
+https://www.erowid.org/chemicals/methoxetamine/methoxetamine_dose.shtml.
+Accessed 2026-05-26.</ref> is marked "very tentative" throughout and
+notes that "doses reported by different users vary by a large amount."
+'''Insufflated:'''
+* Threshold: 5-20 mg; Light: 10-50 mg; Common: 20-60 mg; Strong: 25-100+ mg
+'''Oral:'''
+* Threshold: 8-20 mg; Light: 10-30 mg; Common: 40-60 mg; Strong: 50-100+ mg
+'''Sublingual/buccal:'''
+* Threshold: 5-10 mg; Light: 8-25 mg; Common: 15-50 mg; Strong: 40-100+ mg
+'''Intramuscular:'''
+* Threshold: 3-8 mg; Light: 5-20 mg; Common: 15-30 mg; Strong: 20-80+ mg
+Timing data are not provided by Erowid. The wide variability between
+users (some report strong effects at 50 mg; others minimal at the
+same dose) and Erowid's tentative qualifier should be reflected in
+any presentation.
+</titration>
+| effects            =
+| interactions       = <pharmaInteractions/>
+| pregnancy_details  =
+| monitoring         =
+| counseling         =
+| anecdotes          =
+| seealso            =
+| references         =
 }}
+[[Category:Research chemicals]]
+[[Category:Arylcyclohexylamines]]
 [[Category:Dissociatives]]
+[[Category:Dissociative Anesthetics]]
+[[Category:NMDA receptor antagonists]]

MDElliottMD (talk | contribs)